Latvija - latviešu - Zāļu valsts aģentūra

amomed pharma gmbh, austria - landiolola hidrohlorīds - pulveris infūziju šķīduma pagatavošanai - 600 mg

Latvija - latviešu - Zāļu valsts aģentūra

amomed pharma gmbh, austria - landiolola hidrohlorīds - pulveris infūziju šķīduma pagatavošanai - 300 mg

Latvija - latviešu - Zāļu valsts aģentūra

amomed pharma gmbh, austria - landiolola hidrohlorīds - koncentrāts injekciju šķīduma pagatavošanai - 20 mg/2 ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiplā skleroze - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - bisoprololi fumaras, skābes acetylsalicylicum - kapsula, cietā - 10 mg/75 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - bisoprololi fumaras, skābes acetylsalicylicum - kapsula, cietā - 5 mg/75 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - bisoprololi fumaras, skābes acetylsalicylicum - kapsula, cietā - 5 mg/100 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - bisoprololi fumaras, skābes acetylsalicylicum - kapsula, cietā - 10 mg/100 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hidrohlorīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 un 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.